FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3060703051> ?p ?o ?g. }

• W3060703051 endingPage "e0236156" @default.
• W3060703051 startingPage "e0236156" @default.
• W3060703051 abstract "Background HIV drug resistance (HIVDR) poses a threat to the HIV epidemic control in Zambia especially in sub-populations such as the 15-24 years where there is poor virological suppression. Understanding the prevalence and patterns of HIVDR in this population (15-24 years) will contribute to defining effective antiretroviral therapy (ART) regimens, improving clinical decision making, and supporting behavioral change interventions needed to achieve HIV epidemic control. Methods A cross-sectional analysis of study enrollment data from the Project YES! Youth Engaging for Success randomized controlled trial was conducted. Participants were 15 to 24 years old, who knew their HIV status, and had been on ART for at least 6 months. All participants completed a survey and underwent viral load (VL) testing. Participants with viral failure (VL ≥1,000 copies/mL) underwent HIVDR testing which included analysis of mutations in the protease and reverse transcriptase genes. Results A total of 99 out of 273 analyzed participants receiving ART had VL failure, of whom 77 had successful HIVDR amplification and analysis. Out of the 77, 75% (58) had at least one drug resistant mutation, among which 83% (48/58) required a drug change. Among the 58 with HIVDR mutations, the prevalence of at least one HIVDR mutation to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) were 81%, 65.5% and 1.7%. The mutation M184V which confers resistance to NRTI drugs of lamivudine (3TC) and emtricitabine (FTC) was the most common (81%) among NRTI associated mutations followed by K65R (34.5%) which is associated with both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) resistance. Thymidine analogue mutations (TAMs) which confer resistance primarily to zidovudine (AZT), stavudine (d4T) and other NRTIs were observed at 32.8%. Common TAMs were K70RTQNE (32.8%), K219QE (22.4%), D67N (17.2%) and T215IT (15.5%). The most common NNRTI associated mutation was the K103N (65.5%) which confers resistance to both efavirenz (EFV) and nevirapine (NVP). There was a relatively high occurrence of other NNRTI mutations V106A (36.2%), as well as Y188C (36.2%) and Y181C (36.2%) which confer resistance to etravirine. Conclusions There is a high prevalence of HIVDR including TAMs despite majority of these patients (90.48%) being on AZT or d4T sparing first line ART among the youth. Emergence of these mutations including the NNRTI associated mutations (Y181C and Y188C) may compromise future second- and third-line regimens in the absence of routine HIVDR testing. HIVDR monitoring at start of ART or at first-line failure can better inform clinical decision making and ART programing." @default.
• W3060703051 created "2020-08-24" @default.
• W3060703051 creator A5008740706 @default.
• W3060703051 creator A5020459700 @default.
• W3060703051 creator A5029551276 @default.
• W3060703051 creator A5059059882 @default.
• W3060703051 creator A5059081413 @default.
• W3060703051 creator A5062300799 @default.
• W3060703051 creator A5072846520 @default.
• W3060703051 creator A5078804029 @default.
• W3060703051 creator A5084303270 @default.
• W3060703051 creator A5085430285 @default.
• W3060703051 creator A5086134502 @default.
• W3060703051 creator A5089789276 @default.
• W3060703051 date "2020-08-17" @default.
• W3060703051 modified "2023-10-18" @default.
• W3060703051 title "Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia" @default.
• W3060703051 cites W1909445044 @default.
• W3060703051 cites W2013541284 @default.
• W3060703051 cites W2038084391 @default.
• W3060703051 cites W2051489917 @default.
• W3060703051 cites W2072276094 @default.
• W3060703051 cites W2123409048 @default.
• W3060703051 cites W2147600989 @default.
• W3060703051 cites W2168797913 @default.
• W3060703051 cites W2335763040 @default.
• W3060703051 cites W2344385793 @default.
• W3060703051 cites W2517309668 @default.
• W3060703051 cites W2526215611 @default.
• W3060703051 cites W2671862462 @default.
• W3060703051 cites W2733275326 @default.
• W3060703051 cites W2740227497 @default.
• W3060703051 cites W2766522384 @default.
• W3060703051 cites W2791219759 @default.
• W3060703051 cites W2804301217 @default.
• W3060703051 cites W2808255057 @default.
• W3060703051 cites W2896196515 @default.
• W3060703051 doi "https://doi.org/10.1371/journal.pone.0236156" @default.
• W3060703051 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7430722" @default.
• W3060703051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32804970" @default.
• W3060703051 hasPublicationYear "2020" @default.
• W3060703051 type Work @default.
• W3060703051 sameAs 3060703051 @default.
• W3060703051 citedByCount "8" @default.
• W3060703051 countsByYear W30607030512021 @default.
• W3060703051 countsByYear W30607030512022 @default.
• W3060703051 countsByYear W30607030512023 @default.
• W3060703051 crossrefType "journal-article" @default.
• W3060703051 hasAuthorship W3060703051A5008740706 @default.
• W3060703051 hasAuthorship W3060703051A5020459700 @default.
• W3060703051 hasAuthorship W3060703051A5029551276 @default.
• W3060703051 hasAuthorship W3060703051A5059059882 @default.
• W3060703051 hasAuthorship W3060703051A5059081413 @default.
• W3060703051 hasAuthorship W3060703051A5062300799 @default.
• W3060703051 hasAuthorship W3060703051A5072846520 @default.
• W3060703051 hasAuthorship W3060703051A5078804029 @default.
• W3060703051 hasAuthorship W3060703051A5084303270 @default.
• W3060703051 hasAuthorship W3060703051A5085430285 @default.
• W3060703051 hasAuthorship W3060703051A5086134502 @default.
• W3060703051 hasAuthorship W3060703051A5089789276 @default.
• W3060703051 hasBestOaLocation W30607030511 @default.
• W3060703051 hasConcept C114851261 @default.
• W3060703051 hasConcept C118552586 @default.
• W3060703051 hasConcept C142462285 @default.
• W3060703051 hasConcept C159047783 @default.
• W3060703051 hasConcept C18903297 @default.
• W3060703051 hasConcept C205545832 @default.
• W3060703051 hasConcept C2778451633 @default.
• W3060703051 hasConcept C2779690655 @default.
• W3060703051 hasConcept C2780035454 @default.
• W3060703051 hasConcept C2780727368 @default.
• W3060703051 hasConcept C2993143319 @default.
• W3060703051 hasConcept C3013748606 @default.
• W3060703051 hasConcept C3018457394 @default.
• W3060703051 hasConcept C3019165603 @default.
• W3060703051 hasConcept C54355233 @default.
• W3060703051 hasConcept C57473165 @default.
• W3060703051 hasConcept C71924100 @default.
• W3060703051 hasConcept C74909509 @default.
• W3060703051 hasConcept C86803240 @default.
• W3060703051 hasConceptScore W3060703051C114851261 @default.
• W3060703051 hasConceptScore W3060703051C118552586 @default.
• W3060703051 hasConceptScore W3060703051C142462285 @default.
• W3060703051 hasConceptScore W3060703051C159047783 @default.
• W3060703051 hasConceptScore W3060703051C18903297 @default.
• W3060703051 hasConceptScore W3060703051C205545832 @default.
• W3060703051 hasConceptScore W3060703051C2778451633 @default.
• W3060703051 hasConceptScore W3060703051C2779690655 @default.
• W3060703051 hasConceptScore W3060703051C2780035454 @default.
• W3060703051 hasConceptScore W3060703051C2780727368 @default.
• W3060703051 hasConceptScore W3060703051C2993143319 @default.
• W3060703051 hasConceptScore W3060703051C3013748606 @default.
• W3060703051 hasConceptScore W3060703051C3018457394 @default.
• W3060703051 hasConceptScore W3060703051C3019165603 @default.
• W3060703051 hasConceptScore W3060703051C54355233 @default.
• W3060703051 hasConceptScore W3060703051C57473165 @default.
• W3060703051 hasConceptScore W3060703051C71924100 @default.
• W3060703051 hasConceptScore W3060703051C74909509 @default.

• next